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Abstract: New data have re-established the importance of anticoagulation of patients with ST 
segment elevation myocardial infarction (STEMI), both as an adjuvant to reperfusion therapy or 
in patients ineligible for reperfusion. Recent randomized trials have found newer agents to be 
superior to conventional unfractionated heparin. This article summarizes current understanding 
of the underlying pathophysiology of STEMI and provides a comprehensive review of emerg-
ing trial data for low molecular weight heparins, anti-factor Xa agents and direct thrombin 
inhibitors in this setting.
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Introduction
The contemporary approach to a patient with ischemic-type chest pain is to categorize 
them as experiencing an acute coronary syndrome (ACS) with or without ST segment 
elevation. The assessment of the initial 12-lead electrocardiogram (ECG) is therefore 
of critical importance as the management strategy is different for each group (Antman 
et al 2004; Braunwald et al 2002). Prompt identiﬁ  cation of patients with acute ST 
segment elevation myocardial infarction (STEMI) is vital if patients are to beneﬁ  t 
from contemporary management strategies. Over the last 3 decades, major advances 
in our understanding of the pathophysiological processes responsible for STEMI and 
its sequelae have allowed development of pharmacological therapies to target these 
different processes. Numerous large well designed randomized controlled trials have 
guided determination of ever superior management strategies and their increasing 
utilization has been associated with a corresponding steady decline in death from 
acute myocardial infarction (MI) (Goldberg et al 2004).
Pathophysiology of STEMI
Complex inﬂ  ammatory mechanisms are now known to participate in all stages of 
coronary artery disease, from the initial development of the fatty streak, through 
progression to advanced atherosclerotic lesions causing angina pectoris, to plaque 
disruption and thrombus formation. Plaques vulnerable to disruption and rupture are 
frequently non-obstructive but have a large lipid-rich core and a high macrophage 
content leading to thinning of the ﬁ  brous cap (Moreno et al 1994; Davies 2000; Shah 
2003). Plaque rupture, which typically occurs at the edge or shoulder region, exposes 
the lipid core, leading to platelet adhesion and aggregation, activation of the coagulation 
cascade, and formation of a platelet rich thrombus. A key step in this process is activa-
tion of prothrombin to thrombin (factor IIa) which promotes the formation of ﬁ  brin, 
the protein which acts as a scaffold in stable thrombus. The fate of the thrombus then 
ranges from simple incorporation into the plaque, through subtotal artery occlusion, Vascular Health and Risk Management 2008:4(2) 306
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to fully occlusive thrombus formation (Corti et al 2003), the 
latter typically presenting clinically as STEMI (DeWood 
et al 1980).
Reperfusion strategies for STEMI
Where possible, the immediate treatment goal in STEMI is 
to disperse the thrombus thereby restoring coronary blood 
ﬂ  ow to the culprit artery (Antman et al 2004) in order to 
limit infarct size, to preserve left ventricular function, and 
ultimately, to reduce mortality.
Two decades on from the landmark GISSI trial with 
streptokinase, ﬁ  brinolytic therapy remains the most widely 
used reperfusion strategy (Gruppo Italiano per lo Studio della 
Streptochinasi nell’Infarto Miocardico (GISSI) 1986). Sec-
ond and third generation ﬁ  brinolytic agents interact directly 
with clot-bound plasminogen improving ﬁ  brin selectivity and 
achieve higher rates of early patency although this has trans-
lated at most into only a small further reduction in mortality. 
More important than the ﬁ  brinolytic agent used is the time 
delay from symptom onset to drug administration (Fibrino-
lytic Therapy Trialists’ (FTT) Collaborative Group 1994; 
Boersma et al 1996) and hence the value of third generation 
bolus agents which help facilitate pre-hospital use.
Catheter based reperfusion with primary percutane-
ous coronary intervention (PCI) where available within a 
reasonable timeframe, may lead to even better reduction in 
cardiovascular events, except in patients who present very 
rapidly after symptom onset when both strategies appear to be 
equivalent (Keeley et al 2003; Steg et al 2003). Primary PCI 
is associated with a reduced risk of bleeding complications, in 
particular intracranial hemorrhage (Keeley et al 2003) which 
typically occurs in approximately 1% of patients treated 
with a ﬁ  brinolytic based regimen. Trials have shown that the 
adjuvant anticoagulant dose may play a signiﬁ  cant role in the 
risk of intracranial hemorrhage (Giugliano et al 2001).
Adjuvant antiplatelet therapy
The importance of adjuvant aspirin was established in ISIS-2 
(ISIS-2 (Second International Study of Infarct Survival) 
Collaborative Group 1988) and the value of concurrent clopi-
dogrel in the more recent CLARITY and COMMIT trials 
(Chen et al 2005; Sabatine et al 2005). It is likely that their 
primary beneﬁ  t is to reduce reocclusion following successful 
reperfusion (Scirica et al 2006). Initial trials of glycoprotein 
IIbIIIa receptor antagonists in combination with reduced dose 
ﬁ  brinolytic appeared promising, improving early patency 
and ST resolution (Antman et al 1999). However the large 
GUSTO V trial found only a small efﬁ  cacy advantage in 
selected subgroups which was offset by a signiﬁ  cant increase 
in bleeding risk (Gurm et al 2004).
Adjuvant anticoagulant therapy
While adjuvant anticoagulant therapy may give a small 
improvement in patency (Ross et al 2001), like antiplatelet 
therapy, its main role is in helping to maintain patency 
after successful reperfusion. Additional potential beneﬁ  ts 
include prevention of deep venous thrombosis, pulmonary 
embolism and left ventricular thrombus. Current therapy 
choices include conventional unfractionated heparin (UFH) 
and newer agents, in particular low molecular weight heparin 
(LMWH), factor Xa inhibitors and direct thrombin inhibi-
tors. The mechanism of action of these agents is illustrated 
in Figure 1.
The guidelines mandate the concomitant use of 
anti-coagulant treatment with either pharmacological 
or mechanical reperfusion (Antman et al 2004). An area of 
controversy has existed regarding the need of otherwise for 
anticoagulation with streptokinase as the latter induces pro-
longed ﬁ  brin depletion. Two meta-analyses, both published in 
1996, failed to show evidence of clear beneﬁ  t with adjuvant 
UFH (Collins et al 1996; Mahaffey et al 1996). However, 
more recent placebo controlled data have demonstrated 
beneﬁ  t for use of concomitant LMWH (Simoons et al 2002; 
Yusuf et al 2005) and factor Xa inhibition (Yusuf et al 2006) 
with streptokinase. Of note there is a paucity of placebo-
controlled evidence for use of adjuvant anticoagulation with 
the ﬁ  brin-speciﬁ  c agents, or indeed primary PCI, mainly 
because of a presumption that anticoagulation use in these 
settings is clearly indicated.
Unfractionated heparin
Heparin is a heterogeneous mucopolysaccharide which inter-
acts with antithrombin-III greatly increasing its inhibitory 
effects on thrombin (Hirsh and Fuster 1994). The heparin-
antithrombin-III complex also has inhibitory effects on factor 
Xa and other clotting factors. Use of concurrent intravenous 
heparin has been shown to decrease early thrombin activ-
ity, improve culprit artery patency and reduce reocclusion, 
although the value of delayed subcutaneous (SC) heparin 
following ﬁ  brinolytic therapy is less clear (The GUSTO 
Angiographic Investigators 1993; Mahaffey et al 1996; 
Granger et al 1998). A recent meta-analysis failed to show 
a clear beneﬁ  t for UFH compared to placebo (Eikelboom 
et al 2005). A major drawback with UFH is the signiﬁ  cant 
variability in therapeutic response which occurs because 
of its heterogeneous composition and necessitates close Vascular Health and Risk Management 2008:4(2) 307
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monitoring of the activated partial thromboplastin time 
(aPTT). The typical regimen for use in STEMI is an initial 
bolus of 60 U/kg (max 4000 U) and continued as an infu-
sion of 12 U/kg/hr (max 1000 U/hr) for 48 hours adjusted to 
achieve an aPTT of 50–70 seconds. It is notoriously difﬁ  cult 
to achieve and maintain the aPTT within this target range, 
and under-treatment is a signiﬁ  cant problem. In the TIMI 9B 
trial only approximately one third of patients had an aPTT 
within the target range at any given time, with between 
25%–52% having sub-therapeutic levels (Antman et al 1996). 
Ensuring that the aPTT does not rise above 70 seconds is 
of vital importance because, once exceeded, the absolute 
risk of intracranial hemorrhage rises in direct proportion to 
the aPTT (Granger et al 1996). UFH can also give rise to 
an immunologically mediated thrombocytopenia known as 
heparin induced thrombocytopenia (HIT) which is rare but 
potentially life threatening. These drawbacks, together with 
the requirement for continuous intravenous (IV) administra-
tion, make UFH a less than ideal anticoagulant agent.
Low molecular weight heparin
LMWHs are approximately one third of the molecular weight 
of UFH, conferring greater bioavailability following sub-
cutaneous administration (Antman 2001). Weight adjusted 
SC bolus dosing leads to stable and reliable anticoagulation 
without the need for monitoring, meaning they are much 
Extrinsic pathway
activation
Factor VII
Tissue Factor
Factor X
Intrinsic pathway
activation
Factor IX
Factor VII
Fibrinogen
Fibrin
(clot)
Factor Xa
Factor II Factor IIa
(Thrombin)
Factor IIa inhibitors
Indirect (via antithrombin):
UFH
LMWH
Direct:
DTI
Factor Xa inhibitors
Indirect (via antithrombin):
UFH
LMWH
Pentasaccharides -
-
+
+
Figure 1 Interaction of anti-thrombotic agents with coagulation cascade. UFH-antithrombin III complex has approximately equal inhibitory effects on factor Xa and IIa. 
LMWH-antithrombin III complex has greater relative speciﬁ  city for factor Xa. Pentasaccharide-antithrombin III complex acts only on factor Xa.
Abbreviations: UFH, unfractionated heparin; LMWH, low molecular weight heparin; DTI, direct thrombin inhibitors.Vascular Health and Risk Management 2008:4(2) 308
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more convenient to administer in clinical practice. As well as 
improving bioavailability, once binding to antithrombin-III 
occurs, greater relative speciﬁ  city for factor Xa is provided 
when compared to UFH, producing enhanced blockade of the 
coagulation cascade upstream of thrombin generation. The 
ratio of inhibition of factor Xa:IIa varies between agents (for 
enoxaparin the ratio is 3:1) (Armstrong 1997). HIT is less 
common with LMWH compared to UFH (Warkentin et al 
1995), but it is important to remember that, because LMWHs 
are made by depolymerisation of UFH, they can still give 
rise to this condition.
Placebo controlled studies with LMWH have conﬁ  rmed 
the importance of an adjuvant anticoagulant strategy. The 
AMI-SK study of 496 streptokinase treated MI patients 
showed that adjuvant enoxaparin compared with placebo 
improved early patency by 22%, improved early ST-segment 
resolution and was associated with a 36% reduction in 
the composite of death, reinfarction and recurrent angina 
(Simoons et al 2002). The CREATE trial compared the 
LMWH reviparin with placebo in 15570 patients with STEMI 
(Yusuf et al 2005), of whom 73% received ﬁ  brinolytic ther-
apy and 6.1% underwent primary PCI, the remainder being 
treated conservatively. Reviparin signiﬁ  cantly reduced the 
composite endpoint of death, reinfarction and stroke although 
those receiving ﬁ  brinolytic therapy had an increased the risk 
of major bleeding including intracranial hemorrhage (0.4% 
vs 0.1% for reviparin and placebo groups respectively).
Enoxaparin has been extensively compared to UFH fol-
lowing ﬁ  brinolytic therapy for acute MI (see Table 1). Follow-
ing early studies (Baird et al and HART II), the ASSENT-3 
trial randomized over 6000 patients receiving tenecteplase to 
full-dose tenecteplase and enoxaparin, half-dose tenecteplase 
with weight-adjusted low-dose UFH and a 12-hour abcixi-
mab infusion, or full-dose tenecteplase with 48 hours UFH 
(Assessment of the Safety and Efﬁ  cacy of a New Thrombo-
lytic Regimen (ASSENT)-3 Investigators 2001). Administra-
tion of enoxaparin with full dose tenecteplase led to signiﬁ  cant 
reductions in 30-day mortality, in-hospital reinfarction and 
in-hospital recurrent ischemia compared with UFH, with no 
signiﬁ  cant increase in overall bleeding.
However, the ASSENT-3 PLUS study of over 1600 pre-
hospital patients (Wallentin et al 2003) showed an excess of 
intracranial hemorrhage with enoxaparin in patients >75 years, 
suggesting that a dose reduction was needed in this age group. 
The pivotal 20475 patient ExTRACT-TIMI 25 study (Antman 
et al 2006) thus compared UFH (standard bolus and 48 hour 
infusion) with a modiﬁ  ed enoxaparin regimen – standard 
30 mg IV bolus then 1 mg/kg bd until hospital discharge, 
but reduced dose in patients ≥75 yrs (no initial IV bolus, SC 
dose reduced to 0.75 mg/kg) and a reduced frequency (once 
a day) in patients with impaired renal function. Median treat-
ment duration with UFH was 2.0 days (interquartile range 
2.0–2.2) and with enoxaparin was 7.0 days (interquartile range 
4.5–7.5). Enoxaparin was associated with a 17% reduction in 
death or MI (9.9% vs 12%; p < 0.001), excess major bleed-
ing (2.1% vs 1.4%) but no excess of intra-cranial hemorrhage 
(0.8% vs 0.7%; p = 0.14) and overall net clinical beneﬁ  t. 
Although it may be argued that ExTRACT was a comparison 
of treatment durations rather than drugs, even at 48 hours, the 
composite of death, MI and urgent revascularization was sig-
niﬁ  cantly reduced with enoxaparin treatment (6.1% vs 5.3%; 
p = 0.02). Based on ExTRACT trial data, the Food and Drug 
Administation have formally approved enoxaparin for use in 
ST elevation MI.
A planned substudy of the ExTRACT trial (ExTRACT-
PCI) evaluated whether enoxaparin was superior to UFH in 
those STEMI patients (almost a quarter of the total study 
cohort) who received thrombolytic therapy and subse-
quently underwent PCI within 30 days (Gibson et al 2007). 
By 30 days, patients randomised to enoxaparin showed a 
23% relative reduction in death or MI compared to UFH 
(10.7% vs. 13.8%; p = 0.001) without a signiﬁ  cant difference 
in the risk of major bleeding. Almost one half of the patients 
in this substudy underwent PCI while still receiving blinded 
study drug. Again, for this cohort, a reduction in 30 day death 
or MI risk was seen in the enoxaparin group compared to the 
UFH group (13.0% vs 16.7%; p = 0.013) without an increased 
risk of major bleeding.
Pentasaccharides
Pentasaccharides are manufactured to have a chemical struc-
ture similar to the antithrombin-III binding domain (active 
site) of heparin. Binding of pentasaccharide to antithrombin-III 
induces conformational changes leading to selective and potent 
inhibition of factor Xa resulting in greatly reduced thrombin 
generation (Coussement et al 2001). Unlike UFH and LMWH 
there is no inhibitory effect on thrombin molecule itself. 
Pentasaccharides, such as fondaparinux, can therefore be 
considered as synthetic, highly selective, indirect inhibitors of 
factor Xa. Potential advantages of fondaparinux include 100% 
bioavailability after subcutaneous injection, a long half-life of 
15–18 hours allowing for once daily administration, predict-
able anticoagulant effect with no requirement for monitoring, 
and no cross-reactivity with antibodies associated with HIT 
(Walenga et al 1997; Eﬁ  rd and Kockler 2006). Also, selective 
and potent targeting of an upstream step in the coagulation Vascular Health and Risk Management 2008:4(2) 309
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cascade theoretically achieves superior anticoagulation as 
inhibition of one molecule of factor Xa reduces the down-
stream production of many molecules of thrombin (Antman 
2001). Table 2 summarizes the signiﬁ  cant results from the 
2 clinical end-point trials which investigate fondaparinux use 
in STEMI patients.
The PENTALYSE study compared 5–7 days fonda-
parinux (4 mg, 8 mg, or 12 mg, initial dose IV then SC daily) 
with 48–72 hours UFH in 326 STEMI patients being treated 
with aspirin and alteplase (Coussement et al 2001). There was 
no difference in early artery patency determined by 90 minute 
coronary angiography. Patients who did not have coronary 
intervention during the treatment period, showed a trend to 
less reocclusion with fondaparinux (repeat angiography day 
5–7). PENTALYSE reported a trend to increased instrumen-
tal bleeding but no overall increase in hemorrhage.
The large multi-centre OASIS 6 trial (Yusuf et al 2006) is 
the ﬁ  rst large scale trial to report on the efﬁ  cacy and safety of 
fondaparinux in the setting of STEMI and therefore provides 
an extremely important extension of available evidence. It 
enrolled 12092 STEMI patients from 41 countries and ran-
domized them in a complex design to fondaparinux (2.5 mg 
once daily for up to 8 days) or usual care which was deﬁ  ned as 
either placebo alone where UFH was not indicated (stratum 1, 
n = 5658), or UFH for up to 48 hours followed by placebo for 
up to 8 days in patients with an indication for UFH (stratum 2, 
n = 6434). The initial dose of fondaparinux was SC in stratum 
1 and IV in stratum 2. The decision as to whether UFH was 
indicated was not predeﬁ  ned but based on the investigator’s 
judgment. As with ExTRACT, it is important to note that 
stratum 2 was not only comparing 2 anticoagulants, but 
also 2 anticoagulation strategies. UFH was given for up to 
Table 1 Important randomized controlled trials comparing LMWH with UFH in patients treated with ﬁ  brinolytic therapy for STEMI
Trial  Patients  LMWH regimen  UFH regimen  Outcomes
Baird et ala  300  Enoxaparin 40 mg   IV bolus, then   • Signiﬁ  cant reduction in death, non-fatal 
    IV bolus then 40 mg  infusion to maintain      reinfarction or readmission with unstable angina at 
    SC 8 hourly for   aPTT 2–2.5 ×       90 days in favor of enoxaparin.
    4 days  normal for 4 days  • No  signiﬁ  cant difference in major hemorrhage.
HART IIb  400  Enoxaparin 30 mg   IV bolus, then   •  Enoxaparin non-inferior to UFH.
    IV bolus then   infusion to maintain  • No  signiﬁ  cant difference in adverse events.
    1 mg/kg SC 12   aPTT 2–2.5 ×  
  hourly  for  72 hours  normal for 77 hours 
ENTIRE-  483  Enoxaparin 30 mg   IV bolus, then   • No  signiﬁ  cant difference in TIMI 3 ﬂ  ow at 1 hour.
TIMI 23c    IV bolus then   infusion to maintain  • Signiﬁ  cant reduction in death/reinfarction at 
    1 mg/kg SC 12   aPTT 1.5–2.5 ×       30 days for enoxaparin compared with UFH.
    hourly for 8 days or  normal for 36   • No  signiﬁ  cant difference in major bleeding.
  discharge  hours 
ASSENT-3d,e  6095  Enoxaparin 30 mg   IV bolus, then   • Signiﬁ  cant reductions in 30-day mortality, 
    IV bolus then 1 mg/kg  infusion to maintain      in-hospital reinfarction and in-hospital recurrent 
    SC 12 hourly for  aPTT 50–70s for       ischemia for enoxaparin compared with UFH.
    7 days or discharge  48 hours (2038   •   No  signiﬁ  cant increase in overall bleeding.
  (2040  patients)  patients) 
ASSENT-3   1639  Enoxaparin 30 mg   IV bolus, then   •  Reduction in early ischemic events with 
PLUSf  (pre-hospital)  IV bolus then 1 mg/kg  infusion to maintain      enoxaparin.
    SC 12 hourly for  aPTT 50–70s for   •  Excess intracranial hemorrhage in patients 
    7 days or discharge  48 hours     75 years.
ExTRACTg  20475  Enoxaparin 30 mg   IV bolus, then   • Signiﬁ  cant reduction in death or re-infarction.
    IV bolus then   infusion to maintain  • Signiﬁ  cant increase in major bleeding.
    1 mg/kg SC 12   aPTT 1.5–2 ×   • No  signiﬁ  cant difference in intracranial 
    hourly for 8 days or  normal for 48       hemorrhage.
  dischargeh hours
aBaird et al 2002.
bRoss et al 2001.
cAntman et al 2002.
dAssessment of the Safety and Efﬁ  cacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators 2001.
eThird arm in this trial was half-dose tenecteplase with weight-adjusted low-dose UFH and a 12-hour abciximab infusion.
fWallentin et al 2003.
gAntman et al 2006.
hRegimen included a reduced dose in patients 75 years (no initial IV bolus, SC dose reduced to 0.75 mg/kg) and a reduced frequency (once a day) in patients with 
impaired renal function.
Abbreviations: LMWH, low molecular weight heparin; UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.Vascular Health and Risk Management 2008:4(2) 310
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48 hours only, while fondaparinux was given for up to 8 
days. Fibrinolytic therapy was used in 45% of the patients 
(78.0% in stratum 1 and 15.9% in stratum 2), with streptoki-
nase being the most commonly used (approximately 73%). 
Primary PCI was undertaken in 28.9% (0.2% in stratum 1 and 
53.2% in stratum 2). Almost a quarter of patients (23.7%) did 
not receive any reperfusion therapy. The primary endpoint 
(death/re-MI) in stratum 1 patients was signiﬁ  cantly reduced 
by fondaparinux compared with placebo (11.2 vs 14.0; HR 
0.79 [95% CI 0.68–0.92]). This adds to existing evidence 
(from AMI-SK and CREATE trials) conﬁ  rming adjuvant 
antithrombotic therapy is indicated along with ﬁ  brinolytic 
therapy, including streptokinase. In stratum 2 patients, 
there was no signiﬁ  cant reduction in the primary endpoint 
for fondaparinux compared with UFH (8.3 vs 8.7; HR 0.96 
[95% CI 0.81–1.13]). Also of note, in patients undergoing 
primary PCI there was an increase in complications with 
fondaparinux compared with UFH including guide catheter 
thrombosis, abrupt coronary artery closure, new angiographic 
thrombus, or no reﬂ  ow. An interim protocol modiﬁ  cation 
advising additional UFH in fondaparinux patients undergoing 
acute PCI was thus required.
Surprisingly, lower rates were observed for severe hem-
orrhage (44 vs 28; p = 0.06) and for major bleeds (57 vs 39; 
p = 0.07) with fondaparinux compared with placebo in 
stratum 1. This is in contrast to the CREATE trial which 
demonstrated a signiﬁ  cant excess of life-threatening bleed-
ing in patients who received reviparin compared to placebo. 
The reason for a reduction in major bleeding is not well 
understood – some suggesting it may be a consequence 
of better clinical outcome and/or reduced need for urgent 
revascularization. In stratum 2, the rates of severe and major 
bleeds were similar in the 2 groups.
Several conclusions can be drawn from the OASIS-6 trial. 
There is clear beneﬁ  t for fondaparinux in STEMI patients 
without an indication for UFH, where it is as safe as no 
anticoagulation. In conservatively managed STEMI patients 
with an indication for UFH who receive ﬁ  brinolytic therapy, 
fondaparinux is at least as effective and as safe as UFH. 
However, the use of fondaparinux as the sole anticoagulant 
for STEMI patients treated with primary PCI is associated 
with an increased risk of thrombotic complications, and thus 
pre-treatment with UFH before PCI is required.
Direct thrombin inhibitors
Unlike UFH, direct thrombin (factor IIa) inhibitors inactivate 
clot bound thrombin and prevent thrombin induced platelet 
aggregation. In the large GUSTO IIb trial (Metz et al 1998) 
2274 patients treated with ﬁ  brinolytic therapy for STEMI 
were randomly assigned to the direct thrombin inhibitor 
hirudin or UFH. In patients receiving streptokinase, hirudin 
compared with UFH was associated with a reduction in 
30 day death/re-MI (8.6% vs 14.4%; p = 0.004) although 
no difference was seen in patients treated with tissue-type 
plasminogen activator (see Table 3). In the HIT 4 study 
(Neuhaus et al 1999), 1208 patients with STEMI were 
Table 2 Clinical endpoint trials for the use of fondaparinux in STEMI patients
Trial  Patients  Fondaparinux   UFH   Outcomes
 regimen  regimen   
PENTALYSEa  326 patients   4 mg, 8 mg, or   IV bolus, then  •  Fondaparinux as safe and effective as UFH in 
  receiving   12 mg, initial   infusion to       restoring coronary ﬂ  ow and preventing reocclusion.
  ﬁ  brinolytic  dose IV then SC  maintain  
  therapy  once daily for   aPTT 50–75s  
    5–7 days  for 48–72  
     hours 
OASIS-6b   Stratum 1:  2.5 mg SC once   Placebo  •  Fondaparinux associated with a signiﬁ  cant 
  5658 patients  daily for up to         reduction in death or reinfarction compared with 
    8 days        placebo.
       •    Fondaparinux associated with fewer major bleeds 
            than placebo (non-signiﬁ  cant).
  Stratum 2:  2.5 mg IV bolus  IV bolus, then  • No  signiﬁ  cant difference in death or reinfarction 
  6434 patients  then 2.5 mg SC   infusion to       between fondaparinux and UFH arms.
    once daily for   maintain   • No  signiﬁ  cant difference in bleeding.
    up to 8 days  aPTT 1.5–2 ×  
      normal for up  
      to 48 hours 
aCoussement et al 2001.
bYusuf et al 2006.
Abbreviations: UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.Vascular Health and Risk Management 2008:4(2) 311
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treated with aspirin and streptokinase and randomized to 
receive recombinant hirudin or heparin. A trend to earlier 
ST resolution was seen, but no difference in reinfarction, 
mortality or bleeding rates.
A similar direct thrombin inhibitor, bivalirudin, showed 
improved early patency compared with UFH as an adjunct 
to streptokinase in the HERO study (White et al 1997). 
In the large 17073 patient HERO-2 study, bivalirudin as 
an adjunct to streptokinase did not reduce mortality at 
30 days compared with UFH, but did reduce the rate of 
re-infarction within 4 days by 30% (White et al 2001). 
It is noteworthy that, unlike ExTRACT and OASIS-6, 
this trial compared identical treatment durations of the 
anticoagulants under investigation (48 hour infusion). 
The advantage of bivalirudin over UFH in terms of 
reduced reinfarction came at the cost of a relatively small 
increase in moderate bleeding (1.4% vs 1.1%; p = 0.05). 
There was no signiﬁ  cant difference in the risk of severe 
bleeding. This ﬁ  nding of increased moderate bleeding 
is not consistent with previous trials (Kong et al 1999). 
Again, more recently, bivalirudin has been associated with 
reduced bleeding compared with UFH plus antiplatelet 
glycoprotein IIb/IIIa inhibitors during early PCI for non-
ST elevation acute coronary syndromes (Stone et al 2006). 
It is currently being evaluated in the HORIZONS primary 
PCI STEMI trial, which is comparing bivalirudin to heparin 
plus glycoprotein IIb/IIIa inhibitor.
Summary and conclusions
The role of UFH in STEMI, particularly as an adjunct to 
ﬁ  brinolytic therapy, is being strongly challenged by the 
wealth of data surrounding newer anticoagulants includ-
ing LMWH, factor Xa inhibitors and direct thrombin 
inhibitors. The evidence base is strongest for the LMWH 
enoxaparin where meta-analyses of multiple trials and the 
large ExTRACT trial have conﬁ  rmed that enoxaparin (dose-
adjusted for weight, renal function and age ≥75) compared 
with UFH, results in signiﬁ  cant net clinical beneﬁ  t. The 
recently published substudy of ExTRACT demonstrated 
superiority of enoxaparin over UFH in the patients who 
underwent PCI within 30 days of ﬁ  brinolytic therapy for 
STEMI, without a signiﬁ  cant difference in bleeding. The 
results of this study also suggest that for patients com-
menced on adjuvant enoxaparin after ﬁ  brinolytic therapy 
there is no need to switch to UFH if they proceed to PCI 
during the period of anticoagulation. Thus while based 
on current evidence, enoxaparin may be considered the 
anticoagulant of choice in STEMI, the factor Xa inhibitor 
fondaparinux suggests the intriguing possibility of further 
reduction in bleeding risk without loss of efﬁ  cacy. OASIS-6 
has provided important data on ‘real-world’ use of fonda-
parinux, but because of the heterogeneous trial population 
and dependence on local investigator discretion to decide on 
the appropriateness of anticoagulant therapy, drawing ﬁ  rm 
conclusions for contemporary practice is difﬁ  cult. Addi-
Table 3 Evidence for direct thrombin inhibitors as adjuvant anticoagulation for patients with STEMI receiving ﬁ  brinolytic therapy
Trial  Patients  DTI regimen  UFH regimen  Outcomes
GUSTO IIb triala  2274 patients   Hirudin IV   IV bolus, then  •  In patients receiving streptokinase, hirudin 
  treated with   infusion to   infusion to       compared with UFH was associated with a
   ﬁ  brinolytic  maintain aPTT   maintain       reduction death or reinfarction.
  therapy  60–85s for   aPTT 60–85s   •  No signiﬁ  cant difference in death or reinfarction 
    3–5 days  for 3–5 days      for patients treated with tissue-type plasminogen 
             activator.
HIT 4b   1208 patients   Hirudin IV   12500 U   •  No signiﬁ  cant difference in death or reinfarction.
  treated with   bolus followed   twice daily by  •  No signiﬁ  cant difference in bleeding.
  streptokinase  by SC twice daily  SC injection 
    for 5–7 days   
HEROc   412 patients   Bivalirudin IV   IV bolus, then  •  No signiﬁ  cant difference in death or reinfarction.
  treated with   bolus then   infusion for   •  Signiﬁ  cant reduction in major bleeding with 
  streptokinase  infusion for 60 hours  60 hours      bivalirudin.
HERO-2d  17073 patients   Bivalirudin IV  IV bolus, then  •  No signiﬁ  cant difference in 30 day mortality.
  treated with   bolus then  infusion to maintain  •  Bivalirudin signiﬁ  cantly reduced the rate of early
  streptokinase  infusion for 48 hours  aPTT 50–75s for      (4 days) reinfarction.
     48  hours 
aMetz et al 1998.
bNeuhaus et al 1999.
cWhite et al 1997.
dWhite et al 2001
Abbreviations: UFH, unfractionated heparin; DTI, direct thrombin inhibitor; IV. intravenous; SC, subcutaneous.Vascular Health and Risk Management 2008:4(2) 312
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tionally, given the increasing provision of early PCI after 
successful ﬁ  brinolysis or rescue PCI after failed ﬁ  brinolytic 
therapy, the excess of guide catheter thrombosis is an appar-
ent limitation. While the direct thrombin inhibitor bivaliru-
din was associated with increased bleeding compared with 
UFH in HERO-2, more recent trials have focused on its 
potential as a substitute for UFH plus IIbIIIa inhibitors (and 
hence potential for reduced bleeding) during PCI. The ongo-
ing HORIZONS trial will provide important data regarding 
bivalirudin’s role in primary PCI. However as most STEMI 
patients continue to receive a primary ﬁ  brinolytic strategy, 
a head-to-head comparison of fondaparinux and bivaliru-
din with dose adjusted enoxaparin in a clearly-deﬁ  ned, 
ﬁ  brinolytic-treated population is eagerly awaited.
References
Antman EM, Morrow DA, McCabe CH, et al. 2006. Enoxaparin versus 
unfractionated heparin with ﬁ  brinolysis for ST-elevation myocardial 
infarction. The New England Journal of Medicine, 354:1477–88.
Antman EM, Anbe DT, Armstrong PW, et al. 2004. ACC/AHA guide-
lines for the management of patients with ST-elevation myocardial 
infarction – executive summary: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines (Writing Committee to Revise the 1999 Guidelines for the 
Management of Patients With Acute Myocardial Infarction). Circula-
tion, 110:588–636.
Antman EM, Louwerenburg HW, Baars HF, et al. 2002. Enoxaparin as 
adjunctive antithrombin therapy for ST-elevation myocardial infarction: 
results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 
23 Trial. Circulation, 105:1642–9.
Antman EM. 2001. The search for replacements for unfractionated heparin. 
Circulation, 103:2310–14.
Antman EM, Giugliano RP, Gibson CM, et al. 1999. Abciximab facili-
tates the rate and extent of thrombolysis: results of the thrombolysis 
in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. 
Circulation, 99:2720–32.
Antman EM and the TIMI 9B Investigators. 1996. Hirudin in Acute Myo-
cardial Infarction. Thrombolysis and Thrombin Inhibition in Myocardial 
Infarction (TIMI) 9B Trial. Circulation, 94:911–21.
Armstrong PW. 1997. Heparin in acute coronary disease – requiem for a 
heavyweight? The New England Journal of Medicine, 337:492–4.
Assessment of the Safety and Efﬁ  cacy of a New Thrombolytic Regimen 
(ASSENT)-3 Investigators. 2001. Efﬁ  cacy and safety of tenecteplase 
in combination with enoxaparin, abciximab, or unfractionated heparin: 
the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 
358:605–13.
Baird SH, Menown IB, McBride SJ, et al. 2002. Randomized comparison of 
enoxaparin with unfractionated heparin following ﬁ  brinolytic therapy for 
acute myocardial infarction. European Heart Journal, 23:627–32.
Boersma E, Maas AC, Deckers JW, et al. 1996. Early thrombolytic treat-
ment in acute myocardial infarction: reappraisal of the golden hour. 
Lancet, 348:771–5.
Braunwald E, Antman EM, Beasley JW, et al. 2002. ACC/AHA guideline 
update for the management of patients with unstable angina and non-
ST-segment elevation myocardial infarction--2002: summary article: a 
report of the American College of Cardiology/American Heart Associa-
tion Task Force on Practice Guidelines (Committee on the Management 
of Patients With Unstable Angina). Circulation, 106:1893–900.
Chen ZM, Jiang LX, Chen YP, et al. 2005. Addition of clopidogrel to 
aspirin in 45,852 patients with acute myocardial infarction: randomised 
placebo-controlled trial. Lancet, 366:1607–21.
Collins R, MacMahon S, Flather M, et al. 1996. Clinical effects of 
anticoagulant therapy in suspected acute myocardial infarction: 
systematic overview of randomised trials. British Medical Journal, 
313:652–9.
Corti R, Fuster V, Badimon JJ. 2003. Pathogenetic concepts of acute 
coronary syndromes. Journal of the American College of Cardiology, 
41(4 Suppl S):7S–14S.
Coussement PK, Bassand JP, Convens C, et al. 2001. A synthetic factor-Xa 
inhibitor (ORG31540/SR9017A) as an adjunct to ﬁ  brinolysis in acute 
myocardial infarction. The PENTALYSE study. European Heart 
Journal, 22:1716–24.
Davies MJ. 2000. The pathophysiology of acute coronary syndromes. 
Heart, 83:361–6.
DeWood MA, Spores J, Notske R, et al. 1980. Prevalence of total coronary 
occlusion during the early hours of transmural myocardial infarction. 
The New England Journal of Medicine, 303:897–902.
Eﬁ  rd LE, Kockler DR. 2006. Fondaparinux for Thromboembolic Treatment 
and Prophylaxis of Heparin-Induced Thrombocytopenia. The Annals 
of Pharmacotherapy, 40:1383–7.
Eikelboom JW, Quinlan DJ, Mehta SR, et al. 2005. Unfractionated and low-
molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated 
patients with ST-elevation acute myocardial infarction: a meta-analysis 
of the randomized trials. Circulation, 112:3855–67.
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. 1994. Indications 
for ﬁ  brinolytic therapy in suspected acute myocardial infarction: collabo-
rative overview of early mortality and major morbidity results from all 
randomised trials of more than 1000 patients. Lancet, 343:311–22.
Gibson CM, Murphy SA, Montalescot G, et al. 2007. Percutaneous coronary 
intervention in patients receiving enoxaparin or unfractionated heparin 
after ﬁ  brinolytic therapy for ST-segment elevation myocardial infarc-
tion in the ExTRACT-TIMI 25 trial. Journal of the American College 
of Cardiology, 49:2238–46.
Giugliano RP, McCabe CH, Antman EM, et al. 2001. Lower-dose heparin 
with ﬁ  brinolysis is associated with lower rates of intracranial hemor-
rhage. American Heart Journal, 141:742–50.
Goldberg RJ, Spencer FA, Yarzebski J, et al. 2004. A 25-year perspective 
into the changing landscape of patients hospitalized with acute myo-
cardial infarction (the Worcester Heart Attack Study). The American 
Journal of Cardiology, 94:1373–8.
Granger CB, Becker R, Tracy RP, et al. 1998. Thrombin generation, 
inhibition and clinical outcomes in patients with acute myocardial 
infarction treated with thrombolytic therapy and heparin: results from 
the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global 
Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
Journal of the American College of Cardiology, 31:497–505.
Granger CB, Hirsch J, Califf RM, et al. 1996. Activated partial thrombopla-
stin time and outcome after thrombolytic therapy for acute myocardial 
infarction: results from the GUSTO-I trial. Circulation, 93:870–8.
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico 
(GISSI). 1986. Effectiveness of intravenous thrombolytic treatment in 
acute myocardial infarction. Lancet, 1:397–402.
Gurm HS, Lincoff AM, Lee D, et al. 2004. Outcome of acute ST-segment 
elevation myocardial infarction in diabetics treated with ﬁ  brinolytic 
or combination reduced ﬁ  brinolytic therapy and platelet glycoprotein 
IIb/IIIa inhibition: lessons from the GUSTO V trial. Journal of the 
American College of Cardiology, 43:542–8.
Hirsh J, Fuster V. 1994. Guide to anticoagulant therapy. Part 1: Heparin. 
American Heart Association. Circulation, 89:1449–68.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 
1988. Randomised trial of intravenous streptokinase, oral aspirin, both, 
or neither among 17,187 cases of suspected acute myocardial infarction: 
ISIS-2. Lancet, 2:349–60.
Keeley EC, Boura JA, Grines CL. 2003. Primary angioplasty versus intrave-
nous thrombolytic therapy for acute myocardial infarction: a quantita-
tive review of 23 randomised trials. Lancet, 361:13–20.
Kong DF, Topol EJ, Bittl JA, et al. 1999. Clinical outcomes of bivalirudin 
for ischemic heart disease. Circulation, 100:2049–53.Vascular Health and Risk Management 2008:4(2) 313
New anticoagulant strategies in STEMI
Mahaffey KW, Granger CB, Collins R, et al. 1996. Overview of rand-
omized trials of intravenous heparin in patients with acute myocardial 
infarction treated with thrombolytic therapy. The American Journal of 
Cardiology, 77:551–6.
Metz BK, White HD, Granger CB, et al. 1998. Randomized comparison of 
direct thrombin inhibition versus heparin in conjunction with ﬁ  brinolytic 
therapy for acute myocardial infarction: results from the GUSTO-IIb 
Trial. Global Use of Strategies to Open Occluded Coronary Arteries 
in Acute Coronary Syndromes (GUSTO-IIb) Investigators. Journal of 
the American College of Cardiology, 31:1493–8.
Moreno PR, Falk E, Palacios IF, et al. 1994. Macrophage inﬁ  ltration in 
acute coronary syndromes. Implications for plaque rupture. Circula-
tion, 90:775–8.
Neuhaus KL, Molhoek GP, Zeymer U, et al. 1999. Recombinant hirudin 
(lepirudin) for the improvement of thrombolysis with streptokinase in 
patients with acute myocardial infarction: results of the HIT-4 trial. 
Journal of the American College of Cardiology, 34:966–73.
Ross AM, Molhoek P, Lundergan C, et al. 2001. Randomized comparison 
of enoxaparin, a low-molecular-weight heparin, with unfractionated 
heparin adjunctive to recombinant tissue plasminogen activator throm-
bolysis and aspirin: second trial of Heparin and Aspirin Reperfusion 
Therapy (HART II). Circulation, 104:648–52.
Sabatine MS, Cannon CP, Gibson CM, et al. 2005. Addition of clopi-
dogrel to aspirin and ﬁ  brinolytic therapy for myocardial infarction 
with ST-segment elevation. The New England Journal of Medicine, 
352:1179–89.
Scirica BM, Sabatine MS, Morrow DA, et al. 2006. The role of clopidogrel 
in early and sustained arterial patency after ﬁ  brinolysis for ST-segment 
elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. 
Journal of the American College of Cardiology, 48:37–42.
Shah PK. 2003. Mechanisms of plaque vulnerability and rupture. Journal of 
the American College of Cardiology, 41(4 Suppl S):15S–22S.
Simoons M, Krzeminska-Pakula M, Alonso A, et al. 2002. Improved 
reperfusion and clinical outcome with enoxaparin as an adjunct to 
streptokinase thrombolysis in acute myocardial infarction. The AMI-SK 
study. European Heart Journal, 23:1282–90.
Steg PG, Bonnefoy E, Chabaud S, et al. 2003. Impact of time to treatment on 
mortality after prehospital ﬁ  brinolysis or primary angioplasty: data from 
the CAPTIM randomized clinical trial. Circulation, 108:2851–6.
Stone GW, McLaurin BT, Cox DA, et al. 2006. Bivalirudin for patients 
with acute coronary syndromes. The New England Journal of Medicine, 
355:2203–16.
The GUSTO Angiographic Investigators. 1993. The effects of tissue plas-
minogen activator, streptokinase, or both on coronary-artery patency, 
ventricular function, and survival after acute myocardial infarction. The 
New England Journal of Medicine, 329:1615–22.
Walenga JM, Jeske WP, Bara L, et al. 1997. Biochemical and pharmacologic 
rationale for the development of a synthetic heparin pentasaccharide. 
Thrombosis Research, 86:1–36.
Wallentin L, Goldstein P, Armstrong PW, et al. 2003. Efﬁ  cacy and safety 
of tenecteplase in combination with the low-molecular-weight heparin 
enoxaparin or unfractionated heparin in the prehospital setting: the 
Assessment of the Safety and Efﬁ  cacy of a New Thrombolytic Regimen 
(ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
Circulation, 108:135–42.
Warkentin TE, Levine MN, Hirsh J, et al. 1995. Heparin-induced throm-
bocytopenia in patients treated with low-molecular-weight heparin 
or unfractionated heparin. The New England Journal of Medicine, 
332:1330–5.
White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial 
Investigators. 2001. Thrombin-speciﬁ  c anticoagulation with biva-
lirudin versus heparin in patients receiving ﬁ  brinolytic therapy for 
acute myocardial infarction: the HERO-2 randomised trial. Lancet, 
358:1855–63.
White HD, Aylward PE, Frey MJ, et al. 1997. Randomized, double-blind 
comparison of hirulog versus heparin in patients receiving streptoki-
nase and aspirin for acute myocardial infarction (HERO). Hirulog 
Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation, 
96:2155–61.
Yusuf S, Mehta SR, Chrolavicius S, et al. 2006. Effects of fondaparinux on 
mortality and reinfarction in patients with acute ST-segment elevation 
myocardial infarction: the OASIS-6 randomized trial. The Journal of 
the American Medical Association, 295:1519–30.
Yusuf S, Mehta SR, Xie C, et al. 2005. Effects of reviparin, a low-molecular-
weight heparin, on mortality, reinfarction, and strokes in patients with 
acute myocardial infarction presenting with ST-segment elevation. The 
Journal of the American Medical Association, 293:427–35.